AstraZeneca PLC (NASDAQ:AZN) Shares Sold by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC lowered its position in AstraZeneca PLC (NASDAQ:AZN) by 5.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,401 shares of the company’s stock after selling 945 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in AstraZeneca were worth $1,075,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in AZN. Brown Brothers Harriman & Co. lifted its holdings in AstraZeneca by 3.7% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 6,062 shares of the company’s stock worth $473,000 after buying an additional 216 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in AstraZeneca by 62.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 27,329 shares of the company’s stock worth $2,131,000 after buying an additional 10,500 shares in the last quarter. Wealth Alliance lifted its holdings in AstraZeneca by 5.9% in the 2nd quarter. Wealth Alliance now owns 17,440 shares of the company’s stock worth $1,360,000 after buying an additional 975 shares in the last quarter. Argent Trust Co lifted its holdings in AstraZeneca by 9.5% in the 2nd quarter. Argent Trust Co now owns 7,136 shares of the company’s stock worth $557,000 after buying an additional 618 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in AstraZeneca by 51.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 93,467 shares of the company’s stock worth $7,289,000 after buying an additional 31,893 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Price Performance

AZN opened at $65.68 on Thursday. The firm has a market cap of $203.65 billion, a price-to-earnings ratio of 31.43, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company’s 50-day moving average price is $65.98 and its 200 day moving average price is $74.69. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.87 earnings per share. As a group, sell-side analysts expect that AstraZeneca PLC will post 4.11 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.